Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

SIMPLE SUMMARY: Renal medullary carcinoma (RMC) is a rare and highly aggressive renal cell carcinoma, with a median survival of 13 months. Platinum-based chemotherapy is the recommended standard of care for RMC, but no effective salvage regimens have been established to date. Previous comprehensive...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancers (Basel)
Main Authors: Wiele, Andrew J., Surasi, Devaki Shilpa, Rao, Priya, Sircar, Kanishka, Su, Xiaoping, Bathala, Tharakeswara K., Shah, Amishi Y., Jonasch, Eric, Cataldo, Vince D., Genovese, Giannicola, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Msaouel, Pavlos
Format: Artigo
Sprog:Inglês
Udgivet: MDPI 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124338/
https://ncbi.nlm.nih.gov/pubmed/33946504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13092170
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker